Press release, Helsinki, 4 November 2024 at 9:30 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order from a Finnish hospital for two NBS 6 systems. The customer is new to Nexstim.
The NBS 6 is a new generation Nexstim system that was released in 2023 in the EU and the United States. Developed in collaboration with Nexstim’s customers, the NBS 6 system makes the Company’s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before. The NBS 6 system is currently CE-marked for the treatment of major depression and chronic neuropathic pain in the EU, and FDA-approved for the treatment of major depressive disorder in the United States.
Mikko Karvinen, CEO of Nexstim, comments: “Earlier this year, the Council for Choices in Health Care in Finland added rTMS in the treatment of drug-resistant depression to their list of recommended services that should be included in the range of public health services in Finland. We are glad that the effectiveness of TMS as a treatment option is increasingly recognized, and that so many hospitals and other customers in Finland have chosen Nexstim as their navigated TMS system provider. A warm welcome to this new hospital into our growing user community.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com